Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Brand Name
Micardis
Generic Name
Telmisartan
Active Ingredient
TelmisartanCategory
Angiotensin 2 Receptor Blocker [EPC]
Variants
2
References used for this content
This page is for informational purposes only and does not replace medical advice. Before using any prescription or over-the-counter medication for Micardis, you must consult a qualified healthcare professional.
Detailed information about Micardis
Telmisartan is a potent, long-acting angiotensin II receptor blocker (ARB) used to treat high blood pressure and reduce the risk of cardiovascular events. It works by selectively blocking the AT1 receptor, promoting vasodilation and reducing sodium retention.
Dosage for Telmisartan must be individualized based on the patient's clinical response and the specific condition being treated. According to clinical guidelines and FDA-approved labeling:
As of 2026, the safety and effectiveness of Telmisartan in pediatric patients (under the age of 18) have not been established. Clinical trials in children have been limited, and therefore, it is not currently recommended for use in this population. Parents should consult a pediatric cardiologist or specialist for alternative treatments for childhood hypertension.
For patients with mild to moderate renal impairment, no initial dosage adjustment is typically necessary. Telmisartan is not removed from the blood by hemodialysis. Patients with severe renal impairment or those on dialysis should be monitored closely, as they may be more sensitive to changes in the Renin-Angiotensin system.
Because Telmisartan is primarily eliminated through biliary excretion, patients with hepatic (liver) impairment will experience increased plasma concentrations. For patients with mild to moderate hepatic impairment (Child-Pugh A or B), therapy should be initiated under close medical supervision, and the daily dose should generally not exceed 40 mg.
No overall differences in safety or effectiveness have been observed between elderly patients (65 years and older) and younger patients. However, greater sensitivity in some older individuals cannot be ruled out, and healthcare providers often monitor kidney function and potassium levels more frequently in this demographic.
To ensure the medication works effectively and safely, follow these specific instructions:
If you miss a dose of Telmisartan, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and return to your regular dosing schedule. Do not take two doses at once to make up for a missed one, as this increases the risk of severe hypotension (low blood pressure).
Signs of a Telmisartan overdose may include severe hypotension (dizziness, fainting), tachycardia (fast heart rate), or bradycardia (slow heart rate). If an overdose is suspected, seek emergency medical attention immediately or contact a Poison Control Center. Treatment is generally supportive and focuses on restoring blood pressure and fluid balance.
> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or stop taking the medication without medical guidance, as stopping suddenly can cause a rapid increase in blood pressure.
While Telmisartan is generally well-tolerated, some patients may experience side effects. Common side effects reported in clinical trials (occurring in more than 1% to 10% of patients) include:
Telmisartan is a powerful medication that affects the cardiovascular and renal systems. Patients must be aware of several critical safety considerations. First, blood pressure should be monitored regularly, especially when starting the medication or after a dose increase. Second, patients should stay hydrated, as excessive sweating, vomiting, or diarrhea can lead to a significant drop in blood pressure (hypotension). Finally, patients should not start any new medications, including over-the-counter drugs or supplements, without consulting their healthcare provider.
Fetal Toxicity: Telmisartan can cause serious injury or death to an unborn baby if taken during pregnancy. If you are pregnant or planning to become pregnant, notify your healthcare provider immediately. Telmisartan should be discontinued as soon as pregnancy is confirmed. There are no adequate studies in pregnant women, but the risks to the fetus during the second and third trimesters are well-documented and severe.
Telmisartan must NEVER be used in the following circumstances:
In these situations, the risks may outweigh the benefits, and the drug should only be used under extreme caution and close supervision:
FDA Pregnancy Category D: There is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans. Use of Telmisartan during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death. Resulting oligohydramnios can be associated with fetal lung hypoplasia and skeletal deformations. Potential neonatal adverse effects include skull hypoplasia, anuria, hypotension, renal failure, and death. If pregnancy is confirmed, Telmisartan must be discontinued immediately.
It is not known whether Telmisartan is excreted in human breast milk. However, Telmisartan was shown to be present in the milk of lactating rats. Because of the potential for serious adverse reactions in the nursing infant, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.
Telmisartan is not approved for use in children. Clinical trials in pediatric patients have not demonstrated safety or efficacy. In one study of children aged 6 to 17 years, the blood pressure-lowering effect was not consistently superior to placebo. Therefore, its use is generally restricted to adults.
Telmisartan is a specific and selective antagonist of the Angiotensin II receptor (type AT1). Angiotensin II is the primary vasoactive hormone of the renin-angiotensin-aldosterone system (RAAS) and plays a fundamental role in the pathophysiology of hypertension and heart failure. Telmisartan binds with high affinity to the AT1 receptor subtype, which is responsible for the known actions of angiotensin II, including vasoconstriction, aldosterone release, and renal reabsorption of sodium. By blocking the AT1 receptor, Telmisartan effectively inhibits these processes. Interestingly, Telmisartan has a much lower affinity for the AT2 receptor, which is thought to mediate beneficial effects like vasodilation and anti-proliferation. Furthermore, Telmisartan acts as a partial agonist of PPAR-gamma, a nuclear receptor that regulates glucose and lipid metabolism, which may contribute to its unique metabolic profile compared to other ARBs.
After administration of the first dose, the antihypertensive activity of Telmisartan gradually becomes evident within 3 hours. The maximum reduction in blood pressure is generally attained 4 to 8 weeks after the start of treatment. The antihypertensive effect persists for 24 hours after dosing and remains significant for up to 48 hours, providing a safety margin for patients who might occasionally miss a dose. Telmisartan does not affect heart rate or cardiac output significantly.
Common questions about Micardis
Telmisartan is primarily used to treat essential hypertension, which is high blood pressure that does not have a single identifiable cause. By lowering blood pressure, it helps prevent serious health issues like strokes, heart attacks, and kidney problems. Additionally, it is FDA-approved for cardiovascular risk reduction in patients aged 55 and older who are at high risk of major heart events but cannot tolerate ACE inhibitors. Some doctors may also use it off-label to protect the kidneys in patients with diabetes. It works by relaxing blood vessels so blood can flow more easily throughout the body. Always take this medication exactly as your healthcare provider prescribes for your specific condition.
The most common side effects associated with Telmisartan include upper respiratory tract infections (like the common cold), back pain, and sinus inflammation (sinusitis). Some patients also report experiencing diarrhea, sore throat, or a general feeling of dizziness, especially when standing up quickly. These side effects are usually mild and often diminish as the body adjusts to the medication. However, if any of these symptoms become severe or persistent, you should contact your doctor. It is also important to monitor for more serious but rare reactions like swelling or severe lightheadedness. Your healthcare provider can help you manage these side effects or adjust your treatment plan if necessary.
It is generally advised to limit or avoid alcohol consumption while taking Telmisartan. Alcohol has its own blood pressure-lowering effects, and when combined with Telmisartan, it can cause your blood pressure to drop too low. This may lead to increased side effects such as severe dizziness, lightheadedness, or even fainting (syncope). These risks are particularly high when you first start the medication or when your dose is increased. If you choose to drink, do so in moderation and be very careful when moving from a sitting or lying position to standing. Consult your doctor about what amount of alcohol, if any, is safe for you based on your overall health.
No, Telmisartan is not safe to use during pregnancy and carries a strict Black Box Warning from the FDA. Using this medication during the second and third trimesters can cause severe injury or even death to the developing fetus by interfering with its kidney development and blood pressure regulation. If you discover you are pregnant while taking Telmisartan, you must stop the medication immediately and contact your healthcare provider. They will transition you to a safer alternative for managing your blood pressure during pregnancy. Women of childbearing age should discuss effective birth control methods with their doctor while taking this drug. Protecting fetal health is a priority when managing maternal hypertension.
While Telmisartan begins to lower blood pressure within about 3 hours of taking the first dose, it takes time for the full therapeutic effect to be realized. Most patients will see a significant reduction in their blood pressure readings within two weeks of consistent daily use. However, the maximum blood pressure-lowering effect usually takes between four to eight weeks to achieve. It is important to continue taking the medication every day, even if you do not 'feel' any different, as hypertension often has no outward symptoms. Your doctor will likely schedule follow-up appointments during these first few months to monitor your progress and ensure the dose is correct. Do not stop taking the drug just because your pressure seems normal.
You should never stop taking Telmisartan suddenly without first consulting your healthcare provider. Stopping the medication abruptly will cause your blood pressure to return to its previous high levels, which increases your immediate risk of experiencing a heart attack or stroke. While Telmisartan does not cause a 'rebound' effect as severe as some other classes of blood pressure drugs, consistency is key to long-term cardiovascular health. If you need to stop the medication due to side effects or other concerns, your doctor will provide a plan to gradually reduce your dose or switch you to another medication safely. Always maintain an adequate supply of your prescription to avoid missing doses.
If you miss a dose of Telmisartan, take the missed dose as soon as you remember on that same day. However, if it is almost time for your next scheduled dose, you should skip the missed dose entirely and simply take your next dose at the regular time. Never take two doses at once to 'catch up,' as this can cause your blood pressure to drop to dangerously low levels, leading to dizziness or fainting. To help you remember your medication, try taking it at the same time every day, such as with breakfast. If you frequently miss doses, consider using a pill organizer or setting a daily alarm on your phone. Consistent dosing is vital for the medication to work effectively.
Weight gain is not a commonly reported side effect of Telmisartan in clinical trials. In fact, some research suggests that Telmisartan might have a neutral or even slightly positive effect on metabolism due to its interaction with PPAR-gamma receptors, which are involved in how the body processes fats and sugars. If you notice rapid or unusual weight gain while taking this medication, it is more likely to be caused by fluid retention rather than actual fat gain. Fluid retention can sometimes be a sign of underlying heart or kidney issues that need medical attention. If you experience swelling in your ankles, feet, or hands along with weight gain, notify your healthcare provider immediately for an evaluation. Always discuss any significant weight changes with your doctor.
Telmisartan can interact with several other medications, so it is crucial to provide your doctor with a full list of everything you take. It should not be used with Aliskiren in diabetic patients or with ACE inhibitors, as these combinations increase the risk of kidney failure. Common over-the-counter pain relievers like Ibuprofen or Naproxen (NSAIDs) can reduce the effectiveness of Telmisartan and potentially harm your kidneys. It can also increase the levels of Lithium and Digoxin in your blood, requiring closer monitoring. Potassium supplements and salt substitutes should also be avoided unless directed by your doctor, as they can lead to dangerously high potassium levels. Your pharmacist can also check for potential interactions with any new prescriptions.
Yes, Telmisartan is widely available as a generic medication, which is typically much more affordable than the original brand-name version, Micardis. Generic versions are required by the FDA to have the same active ingredient, strength, dosage form, and route of administration as the brand-name drug. They must also prove bioequivalence, meaning they work in the body the same way as the original. Most insurance plans cover the generic version of Telmisartan. When you fill your prescription, your pharmacist may automatically provide the generic unless your doctor specifically requests the brand name. Generic availability has made this effective blood pressure treatment accessible to a much larger population of patients.
Other drugs with the same active ingredient (Telmisartan)
These effects are less frequent but have been documented in clinical populations:
Rare but potentially significant side effects include:
> Warning: Stop taking Telmisartan and call your doctor immediately or seek emergency care if you experience any of the following:
With prolonged use, the most significant concern is the potential for changes in renal (kidney) function. In patients whose renal function depends on the activity of the RAAS (e.g., patients with renal artery stenosis or severe congestive heart failure), long-term treatment with ARBs like Telmisartan can lead to acute renal failure. Periodic monitoring of serum creatinine and potassium levels is essential for long-term safety.
Telmisartan carries a FDA Black Box Warning regarding fetal toxicity.
Summary of Warning: When pregnancy is detected, Telmisartan must be discontinued as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and even death to the developing fetus. Use of these drugs during the second and third trimesters of pregnancy has been associated with fetal injury, including hypotension, neonatal skull hypoplasia (underdeveloped skull), anuria (lack of urine), reversible or irreversible renal failure, and death. Oligohydramnios (low amniotic fluid) has also been reported, which can result in fetal limb contractures and craniofacial deformation.
Report any unusual symptoms or persistent side effects to your healthcare provider immediately. Your doctor may adjust your dose or switch your medication if side effects become bothersome or dangerous.
To ensure the safe use of Telmisartan, your healthcare provider will likely require periodic lab tests, including:
Telmisartan may cause dizziness or fatigue in some individuals, particularly during the first few weeks of treatment or after a dose increase. Do not drive, operate heavy machinery, or engage in dangerous activities until you know how this medication affects you.
Alcohol can enhance the blood pressure-lowering effect of Telmisartan, which may lead to increased dizziness, lightheadedness, or fainting. It is generally recommended to limit or avoid alcohol consumption while taking this medication.
Do not stop taking Telmisartan suddenly. While it does not typically cause a 'withdrawal syndrome' like beta-blockers, stopping the medication will cause your blood pressure to rise, increasing your risk of heart attack or stroke. If discontinuation is necessary, your doctor will provide a plan to transition to another therapy.
> Important: Discuss all your medical conditions, especially kidney disease, liver disease, or heart failure, with your healthcare provider before starting Telmisartan.
Telmisartan is not known to interfere significantly with common laboratory tests, though it will naturally affect results for serum potassium and creatinine. Always inform laboratory personnel that you are taking an ARB.
Most interactions with Telmisartan are pharmacodynamic (how the drugs affect the body) rather than pharmacokinetic (how the body processes the drug). For example, the interaction with NSAIDs occurs because NSAIDs inhibit prostaglandins that help maintain blood flow to the kidneys, while Telmisartan affects the efferent arteriole of the kidney; together, they can 'triple whammy' the kidney's ability to filter blood.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking to prevent dangerous interactions.
There is a potential for cross-sensitivity in patients who have experienced angioedema with ACE inhibitors. While ARBs are often used as an alternative for these patients, a small percentage may still experience a similar reaction. If you have ever had swelling of the face or throat with any blood pressure medication, your doctor must be informed.
> Important: Your healthcare provider will evaluate your complete medical history, including any history of liver disease or allergies, before prescribing Telmisartan.
In clinical studies, no overall differences in effectiveness or safety were observed between patients over 65 and younger patients. However, the elderly may be more prone to dehydration and may have reduced kidney function, making them more sensitive to the blood pressure-lowering effects. Monitoring for dizziness and falls is recommended in this population.
No initial dosage adjustment is necessary for patients with mild to moderate renal impairment. However, in patients with severe renal impairment (Creatinine Clearance < 30 mL/min), the drug should be used with caution, and potassium levels should be monitored closely. Telmisartan is not dialyzable; therefore, dialysis will not help in the event of an overdose.
Patients with biliary obstructive disorders or hepatic insufficiency should be treated with caution. As Telmisartan is eliminated almost exclusively via the bile, these patients will have higher concentrations of the drug in their blood. The maximum recommended dose for patients with mild to moderate hepatic impairment is 40 mg once daily.
> Important: Special populations require individualized medical assessment and frequent monitoring by a healthcare professional.
| Parameter | Value |
|---|---|
| Bioavailability | 42% - 58% (Dose-dependent) |
| Protein Binding | >99.5% (Albumin & Alpha-1 acid glycoprotein) |
| Half-life | ~24 hours |
| Tmax | 0.5 - 1.0 hour |
| Metabolism | Hepatic (Glucuronidation); No CYP involvement |
| Excretion | Fecal >97%, Renal <1% |
Telmisartan is classified as an Angiotensin II Receptor Blocker (ARB). Related medications in this class include Losartan (Cozaar), Valsartan (Diovan), Olmesartan (Benicar), and Candesartan (Atacand). Among these, Telmisartan is unique for its 24-hour half-life and its high lipophilicity, which allows for excellent tissue penetration.